 | Yeyang Su Ph.D candidate - University of Sussex Medicine |
-
04.08.2015-29.10.2015
The construction and implementation of China's new policy on stem cell clinical trials
This proposed research is designed for understanding how the unfolding policy proposal on stem cell clinical trials is constructed and implemented at the national, provincial and local levels, and understanding people’s encountering and experiences with this new policy in China. It will critically study the structural and institutional power held and performed by science and elite groups evolved during the science policy making and implementation processes, and actively elicit and document opinions and experiences from less heard social groups alongside the same processes. It will further analyze China’s science innovation policies in the context of global competition and collaboration, and compare China’s science advisory and science-policy-making mechanism with those in countries such as the US and the UK. I intend to best use my stay at the Brocher Foundation to analyse and preliminarily theorise my fieldwork data, through my own work and interactions with residents and visitors at the Foundation. -
02.06.2009-08.07.2009
Public engagement in genomic research
Ms. SU Yeyang holds a Master Degree in Genetics from Beijing Institute of Genomics, Chinese Academy of Sciences. During the past three years, alongside her graduate studies, Ms. Su worked as the Director’s Assistant in Bioethics at the Beijing Genomics Institute, and has been working in the International 1000 Genomes Project, the International Cancer Genome Consortium and the BIONET Project. She is currently a junior research fellow of BIONET, and will start her study in the Erasmus Mundus Master Programme of Bioethics in September 2009.
With a specific research interest in public engagement, since March, 2009, Ms. Su has conducted a series of interviews with scientists and researchers from academia and industry, members from patient group and ethics committee, and science communicators from large-scale research project like the UK Biobank and BBMRI, to learn their experience and lessons in public engagement in genomic and bioscience research, and to identify the key factors in good science communication.
Ms. Su also explores the partnerships developed among different stakeholders in nowaday’s biomedical research, and addresses the implications of the massively available biotechnologies, which emerge on the global heath market, like the direct-to-consumer genetic testing.
http://www.bionet-china.org/Default.htm
Previous